Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Cancers|April 3, 2021
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER"Niamh M Keegan, Simon J Furney, Janice M Walshe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaRobert J Motzer, Naomi B Haas, Frede Donskov, et al.
Cancer|June 16, 2018
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancerHanna K Sanoff, Richard M Goldberg, Anastasia Ivanova, et al.
Cancer|April 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignanciesTae Min Kim, Stephen K Williamson, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Cancers|September 28, 2021
Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21)Brian Hayes, Lauren Brady, Gráinne Sheill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.
Pageof 10